High-dose interferon α-2a with ribavirin and amantadine in naïve chronic hepatitis C patients - Results of a randomized, prospective, pilot study

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 12, 2002, Pages 2107-2114

  Ullerich, H ^a   Avenhaus, W ^a   Poremba, C ^a   Domschke, W ^a   Menzel, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFEX; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; APHASIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0036913695     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01379.x     Document Type: Article

References (32)

1. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
2. Poynard T, Marcellin P, Lee S. et al., for the International Hepatitis Interventional Therapy Group (IHIT). Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
3. McHutchison JG, Stuart C, Gordon SC, et al., for the Hepatitis Interventional Therapy Group (HIT). Interferon alpba-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
4. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681-7.
5. Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 989-93.
6. Younossi ZM, Perrillo RP. The roles of amantadine, rimamantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl. 1): 95-102.
7. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-4.
8. Chen SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-40.
9. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs. interferon alone in the retreatment of chronic hepatitis C previously nonresponsive to interferon. J Am Med Assoc 2001; 285: 193-9.
10. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-9.
11. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype I virus with interferon alpha. Hepatology 1997; 26: 226-31.
12. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-56.
13. Neumann AU, Lam NP, Dahari DR, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282: 103-7.
14. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon-alfa on viral turnover. Hepatology 1998; 28: 245-52.
15. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-4.
16. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alpha 2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24: 1034-40.
17. Fried MW, Shiffman ML, Sterling RK. A multicenter, randomized trial of daily high dose interferon alpha-2b, for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype [abstract]. Gastroenterology 1998; 114: A1242(Abstract L0180).
18. Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: A randomized controlled trial. French Multicenter Interferon Study Group. J Viral Hepat 1998; 5: 53-9.
19. Bekkering FC, Brouwer JT, Hansen BE, Schwalm SW. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. J Hepatol 2001; 34(3): 435-40.
20. Goodman ZD, Ishak KG, Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15: 70-81.
21. Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835-41.
22. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
23. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-89.
24. Pawlotski JM, Hepatitis C virus resistance to antiviral therapy. Hepatology 2000; 32: 889-96.
25. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-8.
26. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimes of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
27. Di Marco V, Lo Iacono O, Camma C, et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997; 51: 17-24.
28. Mitchell L, Shiffman MD. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19: 25-33.
29. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-91.
30. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
31. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
32. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.